Tagged with GEN

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Global One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically innovative in terms of the sheer novelty of the medical science, but they are also serving to upend the traditional operating model of the pharma…

Russia The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025, limits on pharma companies’ ability to patent other forms of already known chemical compounds in Russia, and the Sputnik COVID-19 vaccine’s geopolitical cachet.   Russia to allocate $7.4 bln for healthcare…

Singapore Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.   We…

USA Dr Maria T. Millan, president and CEO of the California Institute for Regenerative Medicine (CIRM), shares the Institute’s mission to advance basic and translational research in regenerative medicine in the State of California, their unique funding and operating model, and her perspective on the critical importance of investment in science…

Global Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability to treat and potentially cure many intractable illnesses. To date, however, accessibility to many of these game changing technologies remains limited, often due to high upfront sticker-prices and…

Switzerland A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head of Biogen’s Swiss affiliate and chair of the executive committee of industry association Interpharma, Gasser cites her diverse background as…

Global Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety.  Levy examines why these potentially revolutionary new therapies will necessitate a rethinking and adaptation of currently existing pharmacovigilance processes and activities.   While traditional medicines have, without a…

Global The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies such as CAR-T herald a shift towards genuinely individualized medicine and an exciting new front in the war against cancer,…

Global Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people with few or no alternative treatments. Given the limited amount of long-term evidence for these therapies due to their relatively recent development, however, bringing them to…

USA Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required for novel therapies, why cost effectiveness considerations are on the rise, and the impact of the drug policy environment on payer sentiments.   The US reimbursement landscape…

Global The top ten global generics and biosimilars companies according to a recent Informa Pharma Intelligence ranking for 2019. Sandoz leads the way in terms of revenues from generics, biosimilars, APIs, and OTC drugs, followed by Mylan – which recently merged with Pfizer’s Upjohn unit to form a new company, ‘Viatris’…